MV PHARMA
ActiveMV PHARMA has been active since 2017 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €426k and a net result of €16k. Equity is growing by ~15.7% per year across the filed fiscal years. Its solvency ranks better than 94% of 18040 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.7% (low).
Checked score
Score 2025
73
/ 100
Healthy
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability73▲+4
Solvency100=
Growth52=
Track record100
Bankruptcy probability, 12 months
0.7%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €30k at 30 days acceptable
Liquidity ample (current ratio 6.46 against 5.78 in 2024; short-term debt: 9.2% and cash: 0.6% of total assets), and 9.2% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
90.8%
Return on assets
3.4%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 26-07-2026, 5 days ahead of the deadline.
NBB · 9 filingsDeviation from the deadline
2025
5 d early
2024
4 d early
2023
27 d late
2022
33 d early
2021
2 d early
2020
1 d early
2019
on the day
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
18-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€426k▲ 3.8%
2024 · €410k
2018: €93k
2019: €150k
2020: €236k
2021: €305k
2022: €362k
2023: €409k
2024: €410k
2018 → 2025
Total assets
€469k▲ 2.8%
2024 · €456k
2018: €741k
2019: €769k
2020: €825k
2021: €847k
2022: €880k
2023: €482k
2024: €456k
2018 → 2025
Net result
€16k▲ 926%
2024 · €2k
2018: €59k
2019: €57k
2020: €85k
2021: €69k
2022: €45k
2023: €47k
2024: €2k
2018 → 2025
Working capital
€235k▲ 6.9%
2024 · €220k
2018: €-50k
2019: €-30k
2020: €12k
2021: €39k
2022: €55k
2023: €182k
2024: €220k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€305k-€362k▲ 18.9%€409k▲ 12.9%€410k▲ 0.4%€426k▲ 3.8%
Operating result€96k-€65k▼ 32.2%€69k▲ 6.2%€3k▼ 95.5%€21k▲ 571%
Net result€69k-€45k▼ 34.6%€47k▲ 3.5%€2k▼ 96.7%€16k▲ 926%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 571% above 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €469k
Fixed assets
€191k▲ 0.3%
Current assets
€278k▲ 4.6%
Equity and liabilities €469k
Equity
€426k▲ 3.8%
Debt
€43k▼ 6.4%
The debt ratio falls from 10.1% to 9.2%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€21k▲
2024 · €3k
Cash flow
€16k▲
2024 · €2k
Solvency
90.8%▲
2024 · 89.9%
Current ratio
6.46▲
2024 · 5.78
Quick ratio
6.46▲
2024 · 5.78
Debt / equity
0.10▼
2024 · 0.11
ROE
3.7%▲
2024 · 0.4%
ROA
3.4%▲
2024 · 0.3%
Interest coverage
154.43▲
2024 · 15.31
Debt
€43k▼
2024 · €46k
Debt ≤ 1 year
€43k▼
2024 · €46k
Income taxes
€5k▲
2024 · €1k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€456k€469k▲
Fixed assets21/28€191k€191k▲
Tangible fixed assets22/27€3k€3k▲
Furniture and vehicles24€3k€3k▲
Financial fixed assets28€188k€188k=
Current assets29/58€266k€278k▲
Amounts receivable within one year40/41€239k€275k▲
Trade receivables40€12k€8k▼
Other amounts receivable41€227k€267k▲
Cash at bank and in hand54/58€27k€3k▼
Deferred charges and accrued income490/1€11-
Equity and liabilities
Total equity and liabilities10/49€456k€469k▲
Equity10/15€410k€426k▲
Contributions10/11€20k€20k=
Profit (loss) carried forward14€390k€406k▲
Amounts payable17/49€46k€43k▼
Amounts payable within one year42/48€46k€43k▼
Trade debts44€282€7k▲
Suppliers440/4€282€7k▲
Taxes, remuneration and social security45€2k€5k▲
Taxes450/3€1k€5k▲
Remuneration and social security454/9€478-
Other amounts payable47/48€44k€32k▼
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€133€339▲
Other operating charges640/8€968€474▼
Non-recurring operating charges66A-€2k
Gross operating margin9900€4k€23k▲
Operating profit (loss)9901€3k€21k▲
Financial charges65/66B€212€137▼
Recurring financial charges65€212€137▼
Profit (loss) for the period before taxes9903€3k€21k▲
Income taxes67/77€1k€5k▲
Profit (loss) for the period9904€2k€16k▲
Profit (loss) for the period to be appropriated9905€2k€16k▲
Appropriation of the result
Profit (loss) to be appropriated9906€390k€406k▲
Profit (loss) brought forward from the previous period14P€388k€390k▲
The notes to these accounts (8 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
26-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
27-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
31-12
Financial
Weakest financial yearnet €2k ▼96.7%
Net result drops to €2k, the lowest in the series; recovery starts the following year.
27-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 27 days late
2023
31-12
Financial
Liquidity doublescurrent ratio 3.49
Current ratio from 1.47 to 3.49; short-term debt falls from €115k to €73k.
28-06
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
29-07
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
30-07
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
31-12
Financial
Highest result since 2018net €85k ▲49.5%
Operating result €125k, net result €85k, both a record.
31-12
Financial
Equity above €200kEq €236k ▲56.7%
3 profitable years in a row build equity to €236k.
31-07
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
31-12
Financial
Equity above €150kEq €150k ▲61.2%
2 profitable years in a row build equity to €150k.
02-07
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
2018
26-08
NBB filing
Annual accounts filed
fiscal year 2017 · full schema · 26 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
3 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Saint-Ghislain
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rue des Juifs(B) 947331 Saint-GhislainGround area
339 m²
Building footprint
90 m²
Volume, LiDAR
531 m³
Parcel 53009B0884/00K000, Wallonia · tallest building 6.8 m, ±2 floors. Linked by address, not a title deed.
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 53009B0884/00K000 | Wallonia | 339 m² | 1 · 90 m² | 6.8 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
MEPHAR
BE 0424.193.569
Sint-Niklaas · Eq €426k
APOTHEEK CZIJZ-BATSELIER
BE 0874.514.188
Gent · Eq €426k
RUDOPHAR
BE 0466.316.513
Oostkamp · Eq €426k
KRUISPUNT APOTHEEK
BE 0894.052.958
Antwerpen · Eq €426k
Pharmaphie SDW
BE 0848.603.510
Gent · Eq €426k
Of 5,224 companies in sector 47730 we hold annual accounts for 3,863. 3,419 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded27-03-2017
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 9 filingsAddress and cadastre registers
Data from official sources, last processed on 18-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
1 entryE-mail:info@mvpharma.be